{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:52:55Z","timestamp":1787032375858,"version":"build-2736575974"},"reference-count":35,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Radiotherapy (RT) causes adverse events for which there are no effective treatments. This study investigated the clinical benefits of compound Kushen injection (CKI) in managing radiation injury in patients with lung cancer.\n                    <jats:bold>Methods:<\/jats:bold>\n                    A multicenter, open-label, randomized clinical trial randomly assigned patients with lung cancer to receive either CKI (20 mL\/d for at least 4 weeks) integrated with curative RT (RT + CKI group; n=130) or RT alone (control group; n=130). The primary outcome was the incidence of grade \u22652 radiation-induced lung injury (RILI) in the lungs, esophagus, or heart. Secondary outcomes included patient-reported symptoms, quality of life, objective response rate (ORR), and toxic effects.\n                    <jats:bold>Results:<\/jats:bold>\n                    During the 16-week trial, the RT + CKI group had a significantly lower incidence of grade \u22652 RT-related injury than the control group (12.3% [n=16] vs 23.1% [n=30];\n                    <jats:italic>P<\/jats:italic>\n                    =.02). Compared with the control group, the RT + CKI group experienced a significant decrease in moderate-to-severe symptoms of fatigue, cough, and pain (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.001 for the treatment and time interaction term); significantly less physical symptom interference (\n                    <jats:italic>P<\/jats:italic>\n                    =.01); and significantly better quality of life by the end of the trial (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.05). No statistically significant difference in ORR was found. Adverse reactions associated with CKI were rare.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    This study demonstrated low toxicity of CKI and its effectiveness in patients with lung cancer in reducing the incidence of grade \u22652 RILI and symptom burden, improving patients' quality of life.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2023.7036","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T15:38:43Z","timestamp":1691422723000},"page":"821-830.e3","source":"Crossref","is-referenced-by-count":23,"title":["Compound Kushen Injection Reduces Severe Toxicity and Symptom Burden Associated With Curative Radiotherapy in Patients With Lung Cancer"],"prefix":"10.6004","volume":"21","author":[{"given":"Jie","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxi","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Shelley","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Shi","sequence":"additional","affiliation":[{"name":"School of Public Health, Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hebei Tumor Hospital, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Jin","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojin","family":"Han","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyao","family":"Su","sequence":"additional","affiliation":[{"name":"School of Public Health, Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanghu","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Curr Opin Pulm Med","first-page":"321","article-title":"A contemporary review of radiation pneumonitis","volume":"26","author":"Ullah T","year":"2020","unstructured":"Ullah T, Patel H, Pena GM,  A contemporary review of radiation pneumonitis. Curr Opin Pulm Med 2020;26:321\u2013325."},{"key":"B2","series-title":"Acta Oncol","first-page":"1523","article-title":"Patient-reported lung symptoms and quality of life before and after radiation therapy for non-small cell lung cancer: correlation with radiation pneumonitis and functional imaging","volume":"58","author":"Farr KP","year":"2019","unstructured":"Farr KP, Khalil AA, Grau C. Patient-reported lung symptoms and quality of life before and after radiation therapy for non-small cell lung cancer: correlation with radiation pneumonitis and functional imaging. Acta Oncol 2019;58:1523\u20131527."},{"key":"B3","series-title":"Int J Radiat Oncol Biol Phys","first-page":"444","article-title":"Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis","volume":"85","author":"Palma DA","year":"2013","unstructured":"Palma DA, Senan S, Tsujino K,  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013;85:444\u2013450."},{"key":"B4","series-title":"Lung Cancer","first-page":"222","article-title":"Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy","volume":"108","author":"Koshy M","year":"2017","unstructured":"Koshy M, Malik R, Spiotto M,  Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. Lung Cancer 2017;108:222\u2013227."},{"key":"B5","series-title":"Lung Cancer","first-page":"317","article-title":"Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I\/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone","volume":"40","author":"Jeremic B","year":"2003","unstructured":"Jeremic B, Shibamoto Y, Milicic B,  Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I\/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone. Lung Cancer 2003;40:317\u2013323."},{"key":"B6","series-title":"J Clin Oncol","first-page":"56","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun SG","year":"2017","unstructured":"Chun SG, Hu C, Choy H,  Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol 2017;35:56\u201362."},{"key":"B7","series-title":"Front Oncol","first-page":"584756","article-title":"Intermediate dose-volume parameters, not low-dose bath, is superior to predict radiation pneumonitis for lung cancer treated with intensity-modulated radiotherapy","volume":"10","author":"Meng Y","year":"2020","unstructured":"Meng Y, Luo W, Wang W,  Intermediate dose-volume parameters, not low-dose bath, is superior to predict radiation pneumonitis for lung cancer treated with intensity-modulated radiotherapy. Front Oncol 2020;10:584756."},{"key":"B8","series-title":"Oncology","first-page":"61","article-title":"Use of amifostine for cytoprotection during radiation therapy: a review","volume":"98","author":"King M","year":"2020","unstructured":"King M, Joseph S, Albert A,  Use of amifostine for cytoprotection during radiation therapy: a review. Oncology 2020;98:61\u201380."},{"key":"B9","series-title":"Med Oncol","first-page":"405","article-title":"Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy: a randomized, placebo-controlled study","volume":"32","author":"Bao P","year":"2015","unstructured":"Bao P, Zhao W, Li Y,  Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy: a randomized, placebo-controlled study. Med Oncol 2015;32:405."},{"key":"B10","series-title":"Chest","first-page":"150","article-title":"Radiation-induced lung injury: assessment and management","volume":"156","author":"Hanania AN","year":"2019","unstructured":"Hanania AN, Mainwaring W, Ghebre YT,  Radiation-induced lung injury: assessment and management. Chest 2019;156:150\u2013162."},{"key":"B11","series-title":"Acta Pharmacol Sin","first-page":"676","article-title":"Anti-tumor activities of active ingredients in compound Kushen injection","volume":"36","author":"Wang W","year":"2015","unstructured":"Wang W, You RL, Qin WJ,  Anti-tumor activities of active ingredients in compound Kushen injection. Acta Pharmacol Sin 2015;36:676\u2013679."},{"key":"B12","series-title":"Molecules","first-page":"6481","article-title":"Antioxidant and immunity activities of Fufang Kushen injection liquid","volume":"17","author":"Zhou SK","year":"2012","unstructured":"Zhou SK, Zhang RL, Xu YF,  Antioxidant and immunity activities of Fufang Kushen injection liquid. Molecules 2012;17:6481\u20136490."},{"key":"B13","series-title":"Cancer Lett","first-page":"232","article-title":"Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways","volume":"355","author":"Zhao Z","year":"2014","unstructured":"Zhao Z, Fan H, Higgins T,  Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways. Cancer Lett 2014;355:232\u2013241."},{"key":"B14","series-title":"Front Pharmacol","first-page":"1470","article-title":"The optimal Chinese herbal injections for use with radiotherapy to treat esophageal cancer: a systematic review and Bayesian network meta-analysis","volume":"9","author":"Zhang D","year":"2019","unstructured":"Zhang D, Ni M, Wu J,  The optimal Chinese herbal injections for use with radiotherapy to treat esophageal cancer: a systematic review and Bayesian network meta-analysis. Front Pharmacol 2019;9:1470."},{"key":"B15","series-title":"J Cancer Res Ther","first-page":"1298","article-title":"Efficacy of compound Kushen injection plus radiotherapy on nonsmall-cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Wang S","year":"2016","unstructured":"Wang S, Lian X, Sun M,  Efficacy of compound Kushen injection plus radiotherapy on nonsmall-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Ther 2016;12:1298\u20131306."},{"key":"B16","article-title":"NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer","author":"Ganti AKP","unstructured":"Ganti AKP, Loo BW Jr, Bassetti M,  NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 3.2023. Accessed June 12, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B17","article-title":"NCCN Clinical Practice Guidelines in Oncology: Non\u2013Small Cell Lung Cancer","author":"Ettinger DS","unstructured":"Ettinger DS, Wood DE, Aisner DL,  NCCN Clinical Practice Guidelines in Oncology: Non\u2013Small Cell Lung Cancer. Version 3.2023. Accessed June 12, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B18","series-title":"Yaowu Fenxi Zazhi","first-page":"1101","article-title":"Determination of seven components in compound Kushen injection by HPLC and fingerprint study","volume":"42","author":"Wang P","year":"2022","unstructured":"Wang P, Wang J, Duan X. Determination of seven components in compound Kushen injection by HPLC and fingerprint study. Article in Chinese. Yaowu Fenxi Zazhi 2022;42:1101\u20131109."},{"key":"B19","series-title":"Radiother Oncol","first-page":"89","article-title":"Time evolution of regional CT density changes in normal lung after IMRT for NSCLC","volume":"109","author":"Bernchou U","year":"2013","unstructured":"Bernchou U, Schytte T, Bertelsen A,  Time evolution of regional CT density changes in normal lung after IMRT for NSCLC. Radiother Oncol 2013;109:89\u201394."},{"key":"B20","series-title":"Radiother Oncol","first-page":"392","article-title":"Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer","volume":"107","author":"Uyterlinde W","year":"2013","unstructured":"Uyterlinde W, Chen C, Kwint M,  Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. Radiother Oncol 2013;107:392\u2013397."},{"key":"B21","series-title":"Int J Radiat Oncol Biol Phys","first-page":"1341","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox JD","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341\u20131346."},{"key":"B22","series-title":"J Natl Cancer Inst Monogr","first-page":"lgx010","article-title":"Validation and application of the MD Anderson Symptom Inventory for traditional Chinese medicine (MDASI-TCM)","volume":"2017","author":"Li Z","year":"2017","unstructured":"Li Z, Shi Q, Liu M,  Validation and application of the MD Anderson Symptom Inventory for traditional Chinese medicine (MDASI-TCM). J Natl Cancer Inst Monogr 2017;2017:lgx010."},{"key":"B23","series-title":"J Natl Cancer Inst","first-page":"365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson NK","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B,  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365\u2013376."},{"key":"B24","series-title":"Eur J Cancer","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J,  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228\u2013247."},{"key":"B25","article-title":"Common Terminology Criteria for Adverse Events (CTCAE) v4.0","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Accessed December 1, 2022. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"B26","series-title":"Qual Life Res","first-page":"1563","article-title":"Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study","volume":"27","author":"Yue J","year":"2018","unstructured":"Yue J, Shi Q, Xu T,  Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res 2018;27:1563\u20131570."},{"key":"B27","series-title":"Clin Exp Med","first-page":"417","article-title":"Radiation-induced lung injury: latest molecular developments, therapeutic approaches, and clinical guidance","volume":"19","author":"Lu L","year":"2019","unstructured":"Lu L, Sun C, Su Q,  Radiation-induced lung injury: latest molecular developments, therapeutic approaches, and clinical guidance. Clin Exp Med 2019;19:417\u2013426."},{"key":"B28","series-title":"Int J Radiat Oncol Biol Phys","first-page":"915","article-title":"Randomized phase III trial of radiation treatment +\/- amifostine in patients with advanced-stage lung cancer","volume":"51","author":"Antonadou D","year":"2001","unstructured":"Antonadou D, Coliarakis N, Synodinou M,  Randomized phase III trial of radiation treatment +\/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 2001;51:915\u2013922."},{"key":"B29","series-title":"Int J Radiat Oncol Biol Phys","first-page":"402","article-title":"Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer","volume":"57","author":"Antonadou D","year":"2003","unstructured":"Antonadou D, Throuvalas N, Petridis A,  Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;57:402\u2013408."},{"key":"B30","article-title":"Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals","unstructured":"Council for International Organizations of Medical Sciences. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. Accessed July 10, 2023. Available at: https:\/\/cioms.ch\/publications\/product\/benefit-risk-balance-for-marketed-drugs-evaluating-safety-signals\/"},{"key":"B31","series-title":"Liaoning J Trad Chinese Med","first-page":"317","article-title":"Discussion on the prevention and treatment of primary lung cancer by the compound bitter ginseng injection","volume":"45","author":"Fanglei L","year":"2018","unstructured":"Fanglei L, Pengfei W, Chunxiang T,  Discussion on the prevention and treatment of primary lung cancer by the compound bitter ginseng injection. Article in Chinese. Liaoning J Trad Chinese Med 2018;45:317\u2013319."},{"key":"B32","series-title":"Zhongguo Xin Yao Zazhi","first-page":"2065","article-title":"Multi-center, randomized, controlled clinical study of radiation pneumonitis treated with compound matrine injection in primary lung cancer patients","volume":"22","author":"Wei H","year":"2013","unstructured":"Wei H, Jie L, Wen-guang S,  Multi-center, randomized, controlled clinical study of radiation pneumonitis treated with compound matrine injection in primary lung cancer patients. Article in Chinese. Zhongguo Xin Yao Zazhi 2013;22:2065\u20132068."},{"key":"B33","series-title":"Pharm Care and Res","first-page":"45","article-title":"Clinical observation of the compound Kushen injection and radiotherapy in treatment of patients with esophageal carcinoma","volume":"6","author":"Xu-Yuan C","year":"2006","unstructured":"Xu-Yuan C, Xiao-Bo D, Ling Z,  Clinical observation of the compound Kushen injection and radiotherapy in treatment of patients with esophageal carcinoma. Article in Chinese. Pharm Care and Res 2006;6:45\u201347."},{"key":"B34","series-title":"Support Care Cancer","first-page":"825","article-title":"A systematic review and meta-analysis on the use of traditional Chinese medicine compound Kushen injection for bone cancer pain","volume":"22","author":"Yanju B","year":"2014","unstructured":"Yanju B, Yang L, Hua B,  A systematic review and meta-analysis on the use of traditional Chinese medicine compound Kushen injection for bone cancer pain. Support Care Cancer 2014;22:825\u2013836."},{"key":"B35","series-title":"Chinese J Mod Appl Pharm","first-page":"1533","article-title":"Evaluation on efficiency and safety of Compound Kushen Injection in the treatment of non-small cell lung cancer on the basis of pemetrexed and carboplatin","volume":"35","author":"Li J","year":"2018","unstructured":"Li J, Yahong Z, Ying F,  Evaluation on efficiency and safety of Compound Kushen Injection in the treatment of non-small cell lung cancer on the basis of pemetrexed and carboplatin. Article in Chinese. Chinese J Mod Appl Pharm 2018;35:1533\u20131537."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/8\/article-p821.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/8\/article-p821.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/8\/article-p821.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T15:38:43Z","timestamp":1691422723000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/21\/8\/article-p821.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":35,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.7036","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}